Tardive dyskinesia (TD) is an abnormal involuntary movement disorder that arises as a common adverse effect in patients using antipsychotic medications, occurring in an estimated 20% of this population. This condition inflicts a substantial negative impact on patient quality of life and clinical outcomes and contributes to the significant rate of nonadherence to antipsychotic medication regimens.

Tardive Dyskinesia 360 is a resource center built for mental health practitioners, designed to educate providers on the proper screening, diagnosis, and treatment of TD. Explore expert video commentary, patient cases activities, instructional videos, and stay up to date on the latest information related to TD care.

Tardive Dyskinesia


AIMS Instructional Video

Psych Congress co-chair Rakesh Jain, MD, MPH, explains the importance of the Abnormal Involuntary Movement Scale (AIMS) exam in the diagnosis and monitoring of patients with tardive dyskinesia.

From normal (0) to severe (4), see what real tardive dyskinesia movements look like so you can better assess your patients.

Drs. Jain and Kumar provide and in-depth analysis of two new VMAT2 inhibitors approved to treat tardive dyskinesia.


Faisal Kagadkar, MBBS; Shanila Taha, MBBS; Venkatesh Sreeram, MBBS
Joseph McEvoy, MD; Tyson Park, PharmD; Traci Schilling, MD; Emi Terasawa, PhD; Rajeev Ayyagari, PhD; Benjamin Carroll, PharmD
Cherian Verghese, MD; Carlos Singer, MD; Joshua Burke, MS; Scott Siegert, PharmD, Grace Liang, MD
Hubert Fernandez, MD; Mat Davis, PhD; Stewart Factor, DO; Robert Hauser, MD, MBA; Lars Jarskog, MD; Joohi Jimenez-Shahed, MD; Rajeev Kumar, MD, FRCPC; Stanislaw Ochudlo, MD, PhD; William Ondo, MD; Karen Anderson, MD
Michael Polson, MS, PharmD; Chuck Yonan, PharmD; Ted Williams, PharmD, BCPS